212 related articles for article (PubMed ID: 29089643)
1. Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
Walf-Vorderwülbecke V; Pearce K; Brooks T; Hubank M; van den Heuvel-Eibrink MM; Zwaan CM; Adams S; Edwards D; Bartram J; Samarasinghe S; Ancliff P; Khwaja A; Goulden N; Williams G; de Boer J; Williams O
Leukemia; 2018 Apr; 32(4):882-889. PubMed ID: 29089643
[TBL] [Abstract][Full Text] [Related]
2. Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.
Clesham K; Walf-Vorderwülbecke V; Gasparoli L; Virely C; Cantilena S; Tsakaneli A; Inglott S; Adams S; Samarasinghe S; Bartram J; Williams G; de Boer J; Williams O
Leukemia; 2022 Jun; 36(6):1541-1549. PubMed ID: 35368048
[TBL] [Abstract][Full Text] [Related]
3. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
4. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes.
Pattabiraman DR; McGirr C; Shakhbazov K; Barbier V; Krishnan K; Mukhopadhyay P; Hawthorne P; Trezise A; Ding J; Grimmond SM; Papathanasiou P; Alexander WS; Perkins AC; Levesque JP; Winkler IG; Gonda TJ
Blood; 2014 Apr; 123(17):2682-90. PubMed ID: 24596419
[TBL] [Abstract][Full Text] [Related]
5. Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia.
Freisleben F; Modemann F; Muschhammer J; Stamm H; Brauneck F; Krispien A; Bokemeyer C; Kirschner KN; Wellbrock J; Fiedler W
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639011
[TBL] [Abstract][Full Text] [Related]
6. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
[TBL] [Abstract][Full Text] [Related]
7. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.
Zuber J; Rappaport AR; Luo W; Wang E; Chen C; Vaseva AV; Shi J; Weissmueller S; Fellmann C; Taylor MJ; Weissenboeck M; Graeber TG; Kogan SC; Vakoc CR; Lowe SW
Genes Dev; 2011 Aug; 25(15):1628-40. PubMed ID: 21828272
[TBL] [Abstract][Full Text] [Related]
8. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
Takao S; Forbes L; Uni M; Cheng S; Pineda JMB; Tarumoto Y; Cifani P; Minuesa G; Chen C; Kharas MG; Bradley RK; Vakoc CR; Koche RP; Kentsis A
Elife; 2021 Feb; 10():. PubMed ID: 33527899
[TBL] [Abstract][Full Text] [Related]
9. Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia.
He L; Shi L; Du Z; Huang H; Gong R; Ma L; Chen L; Gao S; Lyu J; Gu H
Exp Cell Res; 2018 Aug; 369(1):61-68. PubMed ID: 29750898
[TBL] [Abstract][Full Text] [Related]
10. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
Uttarkar S; Dassé E; Coulibaly A; Steinmann S; Jakobs A; Schomburg C; Trentmann A; Jose J; Schlenke P; Berdel WE; Schmidt TJ; Müller-Tidow C; Frampton J; Klempnauer KH
Blood; 2016 Mar; 127(9):1173-82. PubMed ID: 26631113
[TBL] [Abstract][Full Text] [Related]
11. Peptidomimetic blockade of MYB in acute myeloid leukemia.
Ramaswamy K; Forbes L; Minuesa G; Gindin T; Brown F; Kharas MG; Krivtsov AV; Armstrong SA; Still E; de Stanchina E; Knoechel B; Koche R; Kentsis A
Nat Commun; 2018 Jan; 9(1):110. PubMed ID: 29317678
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Regulation of Bmi1 by Ubiquitination and Proteasomal Degradation Inhibit Bcl-2 in Acute Myeloid Leukemia.
Kushwaha AC; Mohanbhai SJ; Sardoiwala MN; Sood A; Karmakar S; Roy Choudhury S
ACS Appl Mater Interfaces; 2020 Jun; 12(23):25633-25644. PubMed ID: 32453568
[TBL] [Abstract][Full Text] [Related]
13. The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
Armenteros-Monterroso E; Zhao L; Gasparoli L; Brooks T; Pearce K; Mansour MR; Martens JHA; de Boer J; Williams O
Leukemia; 2019 Dec; 33(12):2817-2829. PubMed ID: 31138842
[TBL] [Abstract][Full Text] [Related]
14. Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index.
Li Y; Thomas D; Deutzmann A; Majeti R; Felsher DW; Dill DL
Sci Rep; 2019 Nov; 9(1):16775. PubMed ID: 31727951
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.
Yusenko MV; Biyanee A; Andersson MK; Radetzki S; von Kries JP; Stenman G; Klempnauer KH
Cancer Lett; 2021 Nov; 520():132-142. PubMed ID: 34256093
[TBL] [Abstract][Full Text] [Related]
16. Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells.
Uttarkar S; Piontek T; Dukare S; Schomburg C; Schlenke P; Berdel WE; Müller-Tidow C; Schmidt TJ; Klempnauer KH
Mol Cancer Ther; 2016 Dec; 15(12):2905-2915. PubMed ID: 27707899
[TBL] [Abstract][Full Text] [Related]
17. Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML.
Negri A; Ward C; Bucci A; D'Angelo G; Cauchy P; Radesco A; Ventura AB; Walton DS; Clarke M; Mandriani B; Pappagallo SA; Mondelli P; Liao K; Gargano G; Zaccaria GM; Viggiano L; Lasorsa FM; Ahmed A; Di Molfetta D; Fiermonte G; Cives M; Guarini A; Vegliante MC; Ciavarella S; Frampton J; Volpe G
Cell Death Dis; 2023 Nov; 14(11):763. PubMed ID: 37996430
[TBL] [Abstract][Full Text] [Related]
18. Constitutive ubiquitination and degradation of c-myb by the 26S proteasome during proliferation and differentiation of myeloid cells.
Feiková S; Wolff L; Bies J
Neoplasma; 2000; 47(4):212-8. PubMed ID: 11043824
[TBL] [Abstract][Full Text] [Related]
19. Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.
Nguyen N; Vishwakarma BA; Oakley K; Han Y; Przychodzen B; Maciejewski JP; Du Y
Oncotarget; 2016 Dec; 7(52):86300-86312. PubMed ID: 27863435
[TBL] [Abstract][Full Text] [Related]
20. C/EBPβ sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.
Klempnauer KH
Exp Hematol; 2022 Apr; 108():8-15. PubMed ID: 35032593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]